Chinese herbal medicine is commonly used as a treatment for benign prostatic hyperplasia (BPH), but its efficacy and safety remain to be examined. To compare the efficacy and adverse events of Chinese herbal medicin...Chinese herbal medicine is commonly used as a treatment for benign prostatic hyperplasia (BPH), but its efficacy and safety remain to be examined. To compare the efficacy and adverse events of Chinese herbal medicine alone or used adjuvantly with Western medications for BPH. Two independent reviewers searched the major electronic databases for randomized controlled trials comparing Chinese herbal medicine, either in single or adjuvant use with Western medication, with placebo or Western medication. Relevant journals and grey literature were also hand-searched. The outcome measures included changes in urological symptoms, urodynamic measures, prostate volume and adverse events. The frequency of commonly used herbs was also identified. Out of 13 922 identified citations of publications, 31 studies were included. Eleven studies with a Jadad score i〉 3 were selected for meta-analysis. Chinese herbal medicine was superior to Western medication in improving quality of life and reducing prostate volume. The frequency of adverse events in Chinese herbal medicine was similar to that of placebo and less than that of Western medication. The evidence is too weak to support the efficacy of Chinese herbal medicine for BPH due to the poor methodological quality and small number of trials included. The commonly used herbs identified here should provide insights for future clinical practice and research. Larger randomized controlled trials of better quality are needed to truly evaluate the efficacy of Chinese herbal medicine.展开更多
Prostate cancer(PCa)is one of the most common malignant tumors in the male genitourinary system,ranking second in incidence worldwide.Traditional Chinese medicine(TCM),as an important component of complementary and al...Prostate cancer(PCa)is one of the most common malignant tumors in the male genitourinary system,ranking second in incidence worldwide.Traditional Chinese medicine(TCM),as an important component of complementary and alternative medicine,shows unique advantages in cancer treatment.Chinese herbal medicine is usually composed of multiple ingredients and involves multiple signaling pathways,which showed function of inducing apoptosis of cancer cells,arresting the cell cycle,inhibiting invasion and metastasis,reducing drug resistance,and regulating immune function.Physical therapy is also an important treatment of TCM.Currently,Physical therapy such as acupuncture or Tai Chi and Qigong are gaining increased recognition in the management of PCa,particularly in addressing issues like urinary incontinence and bone metastasis-related pain.This article reviews the TCM treatment and therapy of PCa,in order to provide new research avenues and treatment options for the treatment of PCa with TCM and improve the quality of life of patients.展开更多
Objective:To investigate the effect of Kangquan Recipe(康泉方,KQR)on bone morphogenetic protein and activin membrane-bound inhibitor(BAMBI)expression and its mechanism in rats with benign prostatic hyperplasia(BPH).Me...Objective:To investigate the effect of Kangquan Recipe(康泉方,KQR)on bone morphogenetic protein and activin membrane-bound inhibitor(BAMBI)expression and its mechanism in rats with benign prostatic hyperplasia(BPH).Methods:Forty-eight male Sprague-Dawley rats were divided into 6 groups using a random number table,with 8 in each group:the normal group(normal saline 10 m L/kg),the model group(normal saline 10 m L/kg),the finasteride group(0.5 mg/kg),the low-dose KQR group(3.5 g/kg),the middle-dose KQR group(7 g/kg),and the high-dose KQR group(14 g/kg).The 40 rats were subcutaneously injected with testosterone propionate after castration for 30 days to establish the BPH rat model except for those in the normal group.At the same time,the corresponding drugs were administered by gavage for 30 consecutive days.The effects of different doses of KQR on the protate wet weight,prostate volume and prostate index(PI)were observed.The changes in histopathology were monitored with hematoxylin-eosin staining.BAMBI protein and m RNA expression contents were determined by Western blot and quantitative real-time polymerase chain reaction,respectively.Results:All doses of KQR could decrease prostatic epithelial tissue proliferation.Compared to the model group,the high and middle-dose KQR significantly reduced prostate wet weight,prostate volume and PI;increased BAMBI protein expression in the hypothalamus,pituitary and prostate tissue;all doses of KQR up-regulated BAMBI m RNA expression in serum,prostatic fluid and prostate tissue(P<0.05 or P<0.01).Conclusions:KQR could inhibit the proliferation of rat prostatic tissue,promote BAMBI protein expression in the hypothalamic-pituitary-prostate of rats with BPH;and increase BAMBI m RNA expression in the blood,prostatic fluid and prostate tissue of rats with BPH,showing a dose-effect relationship.KQR can be used as a potential drug for the treatment of BPH.展开更多
Objective:To investigate the effect of Longbishu Capsule(癃闭舒胶囊,LBS),doxazosin,and combination therapy on benign prostatic hyperplasia(BPH).Methods:A randomized,double-blind,multi-center parallel trial was c...Objective:To investigate the effect of Longbishu Capsule(癃闭舒胶囊,LBS),doxazosin,and combination therapy on benign prostatic hyperplasia(BPH).Methods:A randomized,double-blind,multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing(108 cases),Heilongjiang(90 cases),Sichuan(90 cases),Shanghai(72 cases),China.They were randomly assigned with central randomization method to group A(LBS placebo plus doxazosin),group B(LBS plus doxazosin)or group C(LBS plus doxazosin placebo),120 cases for each group.The international prostate symptom score,maximum urinary flow rate,postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments.Results:At baseline,there was no significant difference in the measured variables among the three groups.After 12-month treatment,the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline(P〈0.01).Although postvoid residual urine volume was not significantly different from the baseline in group A(P〉0.05),it significantly decreased in group B and C(P〈0.05).The incidence of adverse events were similar among the three groups.Conclusions:The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH.The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.展开更多
Objective:To observe the effectiveness and safety of Kangquan Recipe(康泉方,KQR) for benign prostatic hyperplasia(BPH) patients.Methods:One hundred and six BPH patients were randomly assigned to the treatment gr...Objective:To observe the effectiveness and safety of Kangquan Recipe(康泉方,KQR) for benign prostatic hyperplasia(BPH) patients.Methods:One hundred and six BPH patients were randomly assigned to the treatment group(53 cases) and the control group(53 cases) according to a random number table.The treatment group was given KQR orally;the control group was given cemilton orally.After 24-week treatment,the clinical effect and safety were evaluated using the International Prostatic Symptom Score(l-PSS),quality of life(QOL),maximum flow rate(Qmax),average flow rate(Qave),residual urine volume(RUV),total prostatic volume(TPV),etc.Results:After treatment,the score of l-PSS was decreased from 16.9 ±5.6 to 12.5 ±4.6in the treatment group,significantly lower compared with the control group;the levels of Qmax and Qave were from 10.9 ±3.5 to 15.6 ±4.5 and 5.4 ±2.1 to 7.3 ±2.5(mL/s) in the treatment group,significantly higher compared with the control group;the levels of RUV and TPV were from 70.8 ±28.2 to 35.2 ±21.8 and37.2 ± 16.9 to 30.1 ± 10.8(mL) in the treatment group,significantly lower compared with the control group(all P〈0.05).The incidence rate of adverse reaction was similar between the two groups(P〉0.05).Conclusion:KQR is effective and safe for the treatment of BPH.展开更多
OBJECTIVE: To investigated the effect and mechanism of Fangjihuangqi Tang (FHT) on lower urinary tract dysfunction induced by benign prostatic hyperplasia (BPH) in rats. METHODS: Male rats were randomly divided into s...OBJECTIVE: To investigated the effect and mechanism of Fangjihuangqi Tang (FHT) on lower urinary tract dysfunction induced by benign prostatic hyperplasia (BPH) in rats. METHODS: Male rats were randomly divided into seven groups: normal, model, finasteride (0.5 mg/ kg), terazosin (0.5 mg/kg), and FHT (10, 5, 2.5 g/kg). Rats were administered testosterone (0.5 mg sc) for 6 weeks after orchiectomy, excluding the normal group. All rats were intragastrically administered assigned drugs for 4 weeks from the third week. Urodynamics were assessed in rats under anesthesia. Serum dihydrotestosterone (DHT) and prostatic acid phosphatase (PAP) were measured. The prostate index (PI), bladder index (BI), and pathological detection were evaluated. RESULTS: In the model group, the PI, BI, serum DHT, serum PAP, threshold pressure (TP), micturition pressure (MP), and residual urine volume (RV)were significantly higher. Moreover, inter-micturition duration (IMD) was significantly lower and the prostatic and bladder showed obvious pathological changes. The IMD was significantly higher, while BI, TP, MP, and RV were significantly lower and bladder pathological changes were alleviated in the FHT (10, 5 g/kg), finasteride, and terazosin groups. The PI, DHT, and PAP were significantly lower in the finasteride group, but they did not change significantly in the FHT (10, 5, 2.5 g/kg) and terazosin groups. CONCLUSION: FHT could relieve symptoms of lower urinary tract dysfunction in BPH rats but with no apparent effect on reducing the volume of the enlarged prostate itself.展开更多
文摘Chinese herbal medicine is commonly used as a treatment for benign prostatic hyperplasia (BPH), but its efficacy and safety remain to be examined. To compare the efficacy and adverse events of Chinese herbal medicine alone or used adjuvantly with Western medications for BPH. Two independent reviewers searched the major electronic databases for randomized controlled trials comparing Chinese herbal medicine, either in single or adjuvant use with Western medication, with placebo or Western medication. Relevant journals and grey literature were also hand-searched. The outcome measures included changes in urological symptoms, urodynamic measures, prostate volume and adverse events. The frequency of commonly used herbs was also identified. Out of 13 922 identified citations of publications, 31 studies were included. Eleven studies with a Jadad score i〉 3 were selected for meta-analysis. Chinese herbal medicine was superior to Western medication in improving quality of life and reducing prostate volume. The frequency of adverse events in Chinese herbal medicine was similar to that of placebo and less than that of Western medication. The evidence is too weak to support the efficacy of Chinese herbal medicine for BPH due to the poor methodological quality and small number of trials included. The commonly used herbs identified here should provide insights for future clinical practice and research. Larger randomized controlled trials of better quality are needed to truly evaluate the efficacy of Chinese herbal medicine.
基金supported by China Postdoctoral Science Foundation(2022M722674)Peixian Science and Technology Plan Project(P202410)Xuzhou Medical Reserve Talents Project(XWRCHT20220009).
文摘Prostate cancer(PCa)is one of the most common malignant tumors in the male genitourinary system,ranking second in incidence worldwide.Traditional Chinese medicine(TCM),as an important component of complementary and alternative medicine,shows unique advantages in cancer treatment.Chinese herbal medicine is usually composed of multiple ingredients and involves multiple signaling pathways,which showed function of inducing apoptosis of cancer cells,arresting the cell cycle,inhibiting invasion and metastasis,reducing drug resistance,and regulating immune function.Physical therapy is also an important treatment of TCM.Currently,Physical therapy such as acupuncture or Tai Chi and Qigong are gaining increased recognition in the management of PCa,particularly in addressing issues like urinary incontinence and bone metastasis-related pain.This article reviews the TCM treatment and therapy of PCa,in order to provide new research avenues and treatment options for the treatment of PCa with TCM and improve the quality of life of patients.
基金Supported by the National Natural Science Foundation of China(No.81674041)the Foundation of Science and Technology Department of Xiamen(No.3502Z20164013)the Natural Science Foundation of Fujian Province(No.2018J01395)。
文摘Objective:To investigate the effect of Kangquan Recipe(康泉方,KQR)on bone morphogenetic protein and activin membrane-bound inhibitor(BAMBI)expression and its mechanism in rats with benign prostatic hyperplasia(BPH).Methods:Forty-eight male Sprague-Dawley rats were divided into 6 groups using a random number table,with 8 in each group:the normal group(normal saline 10 m L/kg),the model group(normal saline 10 m L/kg),the finasteride group(0.5 mg/kg),the low-dose KQR group(3.5 g/kg),the middle-dose KQR group(7 g/kg),and the high-dose KQR group(14 g/kg).The 40 rats were subcutaneously injected with testosterone propionate after castration for 30 days to establish the BPH rat model except for those in the normal group.At the same time,the corresponding drugs were administered by gavage for 30 consecutive days.The effects of different doses of KQR on the protate wet weight,prostate volume and prostate index(PI)were observed.The changes in histopathology were monitored with hematoxylin-eosin staining.BAMBI protein and m RNA expression contents were determined by Western blot and quantitative real-time polymerase chain reaction,respectively.Results:All doses of KQR could decrease prostatic epithelial tissue proliferation.Compared to the model group,the high and middle-dose KQR significantly reduced prostate wet weight,prostate volume and PI;increased BAMBI protein expression in the hypothalamus,pituitary and prostate tissue;all doses of KQR up-regulated BAMBI m RNA expression in serum,prostatic fluid and prostate tissue(P<0.05 or P<0.01).Conclusions:KQR could inhibit the proliferation of rat prostatic tissue,promote BAMBI protein expression in the hypothalamic-pituitary-prostate of rats with BPH;and increase BAMBI m RNA expression in the blood,prostatic fluid and prostate tissue of rats with BPH,showing a dose-effect relationship.KQR can be used as a potential drug for the treatment of BPH.
基金Supported by the Project of Science Research for the 11th FiveYear Plan(No.2007BAI20B044)
文摘Objective:To investigate the effect of Longbishu Capsule(癃闭舒胶囊,LBS),doxazosin,and combination therapy on benign prostatic hyperplasia(BPH).Methods:A randomized,double-blind,multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing(108 cases),Heilongjiang(90 cases),Sichuan(90 cases),Shanghai(72 cases),China.They were randomly assigned with central randomization method to group A(LBS placebo plus doxazosin),group B(LBS plus doxazosin)or group C(LBS plus doxazosin placebo),120 cases for each group.The international prostate symptom score,maximum urinary flow rate,postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments.Results:At baseline,there was no significant difference in the measured variables among the three groups.After 12-month treatment,the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline(P〈0.01).Although postvoid residual urine volume was not significantly different from the baseline in group A(P〉0.05),it significantly decreased in group B and C(P〈0.05).The incidence of adverse events were similar among the three groups.Conclusions:The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH.The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.
基金Supported by the Foundation of Science and Technology Department of Xiamen(No.3502Z20084014)the Foundation ofKey Projects from Science and Technology Department of Fujian Province(No.2012D064)the Foundation of Traditional Chinese Medicine of Fujian Province(No.wst201208)
文摘Objective:To observe the effectiveness and safety of Kangquan Recipe(康泉方,KQR) for benign prostatic hyperplasia(BPH) patients.Methods:One hundred and six BPH patients were randomly assigned to the treatment group(53 cases) and the control group(53 cases) according to a random number table.The treatment group was given KQR orally;the control group was given cemilton orally.After 24-week treatment,the clinical effect and safety were evaluated using the International Prostatic Symptom Score(l-PSS),quality of life(QOL),maximum flow rate(Qmax),average flow rate(Qave),residual urine volume(RUV),total prostatic volume(TPV),etc.Results:After treatment,the score of l-PSS was decreased from 16.9 ±5.6 to 12.5 ±4.6in the treatment group,significantly lower compared with the control group;the levels of Qmax and Qave were from 10.9 ±3.5 to 15.6 ±4.5 and 5.4 ±2.1 to 7.3 ±2.5(mL/s) in the treatment group,significantly higher compared with the control group;the levels of RUV and TPV were from 70.8 ±28.2 to 35.2 ±21.8 and37.2 ± 16.9 to 30.1 ± 10.8(mL) in the treatment group,significantly lower compared with the control group(all P〈0.05).The incidence rate of adverse reaction was similar between the two groups(P〉0.05).Conclusion:KQR is effective and safe for the treatment of BPH.
基金Supported by Natural Science Foundation of the Education Department of Anhui Province,China(No.KJ2010A208)
文摘OBJECTIVE: To investigated the effect and mechanism of Fangjihuangqi Tang (FHT) on lower urinary tract dysfunction induced by benign prostatic hyperplasia (BPH) in rats. METHODS: Male rats were randomly divided into seven groups: normal, model, finasteride (0.5 mg/ kg), terazosin (0.5 mg/kg), and FHT (10, 5, 2.5 g/kg). Rats were administered testosterone (0.5 mg sc) for 6 weeks after orchiectomy, excluding the normal group. All rats were intragastrically administered assigned drugs for 4 weeks from the third week. Urodynamics were assessed in rats under anesthesia. Serum dihydrotestosterone (DHT) and prostatic acid phosphatase (PAP) were measured. The prostate index (PI), bladder index (BI), and pathological detection were evaluated. RESULTS: In the model group, the PI, BI, serum DHT, serum PAP, threshold pressure (TP), micturition pressure (MP), and residual urine volume (RV)were significantly higher. Moreover, inter-micturition duration (IMD) was significantly lower and the prostatic and bladder showed obvious pathological changes. The IMD was significantly higher, while BI, TP, MP, and RV were significantly lower and bladder pathological changes were alleviated in the FHT (10, 5 g/kg), finasteride, and terazosin groups. The PI, DHT, and PAP were significantly lower in the finasteride group, but they did not change significantly in the FHT (10, 5, 2.5 g/kg) and terazosin groups. CONCLUSION: FHT could relieve symptoms of lower urinary tract dysfunction in BPH rats but with no apparent effect on reducing the volume of the enlarged prostate itself.